CCO Oncology Podcast

Essential Biomarker Testing in GI Cancers

Episode Summary

Listen to John L. Marshall, MD, discuss contemporary biomarker testing considerations in gastrointestinal tumors, including colon, gastric, biliary, and pancreas cancers.

Episode Notes

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:

• Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing
• Tumor agnostic testing: MSI, TMB, and NTRK fusion testing
• Colon cancer: RAS, BRAF, and HER2
• Gastric cancer: PD-L1, HER2, and more
• Pancreatic cancer: BRCA
• Biliary cancers: FGFR and IDH1
• Liquid biopsies
• When to test

Presenter:

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Content based on an online CME program supported by educational grants from Bayer and Merck, Sharp & Dohme.

Link to full program:
https://bit.ly/3j4hV8J